Stocktoria
Edesa Biotech, Inc. EDSA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2008-08-25
Edesa Biotech, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| R&D expense | $3.7M | $2.9M | $4.8M | $13.3M | $17.9M |
| Operating income | -$7.9M | -$7.0M | -$9.2M | -$18.4M | -$23.7M |
| Income tax | $800 | $800 | $800 | $800 | $800 |
| Net income | -$7.2M | -$6.2M | -$8.4M | -$17.5M | -$13.3M |
| Operating cash flow | -$7.3M | -$4.9M | -$6.6M | -$12.3M | -$13.7M |
| Free cash flow | — | — | -$6.6M | -$12.3M | -$13.7M |
| Cash & equivalents | $10.8M | $1.0M | $5.4M | $7.1M | $7.8M |
| Total assets | $13.5M | $3.8M | $8.9M | $11.6M | $14.6M |
| Total liabilities | — | $1.8M | $1.8M | $2.2M | $1.5M |
| Shareholders' equity | $12.5M | $2.0M | $7.0M | $9.4M | $13.1M |
Source: SEC EDGAR filings · CIK 0001540159 · as of 2025-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.